cardiology
Heart disease

PCSK9 inhibitors: How low can we and should we go?

Sponsored by Sanofi-aventis Australia Pty Ltd

Ischaemic heart disease remains the leading cause of death in Australia, with lipids one of the modifiable factors to help mitigate risk, particularly in patients at high risk of cardiovascular events. To discuss the new kid on the block – PCSK9 inhibitors – and the role they will play in therapy, the limbic spoke with ...

Already a member?

Enter your email to keep reading.


OR